 This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients who have melanoma lesions deep in the skin, in patients who have had positive lymph nodes, and in patients who have had surgery for metastatic disease cancer that has spread beyond the primary site. Melanoma tumors produce proteins called glycoprotein 100 gp100 and melanoma-associated antigen recognized by T cells 1 MART-1. Vaccination with specific pieces of these proteins peptides may boost the immune systems fight against the cancer. The vaccine injections are mixed with an oil-based substance called Montanide ISA-51, which is intended to increase the immune response to the peptide. 